Merck’s New Cancer Drug Wins Speedy Approval in China
Pharmaceutical giant Merck Sharp & Dohme (MSD) has won approval to launch a cutting-edge cancer drug in China, a month after rival Bristol-Myers Squibb (BMS) obtained the go-ahead for its own such drug.
The MSD medicine, Keytruda, received the green light from the China Food and Drug Administration (CFDA) on Wednesday. The drug can cure certain levels of melanoma, a type of skin cancer.
- 1Chart of the Day: ‘Made in China 2025’ Dropped From List of Local Government Priorities
- 2‘Aquaman’ Makes Huge Splash in China Box Office
- 3Update: Huawei CFO Faces U.S. Fraud Charges, Canadian Court Told
- 4Update: China Logs Record-High Surplus With U.S. Despite Softening Overall Export Growth
- 5It Has Been a Bad Year for the Yuan. 2019 Could Be Worse
- 1Power To The People: Pintec Serves A Booming Consumer Class
- 2Largest hotel group in Europe accepts UnionPay
- 3UnionPay mobile QuickPass debuts in Hong Kong
- 4UnionPay International launches premium catering privilege U Dining Collection
- 5UnionPay International’s U Plan has covered over 1600 stores overseas